AKBA Akebia Therapeutics
Akebia Therapeutics earnings company data as of 4:45 AM ET 11/1
Scheduled
1 period, newest first, nothing reported yet. Each row shows EPS above revenue.
| Period | Date | Metric | Estimate | Actual | Result |
|---|---|---|---|---|---|
| FY2026 Q3 | 5 Nov | EPS | -0.03 | — | — |
| Rev | $46.9M | — | — |
Insider trades
Open-market buys and sales by AKBA's executives, directors and 10% owners in the last 12 months, from their Form 4s
- $87K bought by 1 insider
- None no sales outside a trading plan
- None no planned (10b5-1) sales
-
John P. Butler CEOBuy$87K 69,270 shares at $1.25 +2.1% to stakeTraded Mar 4 Filed Mar 5
Also filed in the last 12 months, not counted as buying or selling: 16 sales to cover taxes, 13 stock grants, and 1 option exercise.
SEC filings
Recent issuer filings from EDGAR, 18 shown.
| Filed | Form | Detail | Links |
|---|---|---|---|
| 8-K | 3.01 | Filing Doc | |
| 8-K | 5.02 | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| 8-K | 7.01,8.01,9.01 | Filing Doc | |
| 8-K | 5.07 | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| DEF 14A | Filing Doc | ||
| DEFA14A | Filing Doc | ||
| 8-K | 5.02,9.01 | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-K | Filing Doc | ||
| SCHEDULE 13G | — | Filing Doc | |
| 8-K | 1.01,2.03,5.02,9.01 | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc |
No filings match this filter.
Estimates are consensus figures; SEC filings remain the official record. Not investment advice.
Further reading
As an Amazon Associate, FollowTheFilings earns from qualifying purchases.
- How to Read a Financial Report (Tracy & Tracy) View on Amazon
- Financial Statements QuickStudy Laminated Guide View on Amazon
- Financial Intelligence, Revised Ed. View on Amazon